Malignant aortic body tumor with metastasis to bone in a dog

Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018

Heart base tumours (HBT) occur commonly in older, brachycephalic dogs. A presumptive diagnosis is made based on location and appearance of the tumour via echocardiogram. Effective treatment options are limited to surgery (when feasible) or radiation therapy. Benefit of medical management is presently unknown. The goal of this retrospective study was to assess the efficacy and tolerability of toceranib phosphate for dogs with HBT. Twenty-eight dogs with histologically, cytologically confirmed or presumed HBT were evaluated retrospectively. Twenty-seven dogs were treated with single agent toceranib. One dog received combination therapy with concurrent metronomic chemotherapy. This dog was not included in response or survival analysis. Factors assessed included clinical signs, hematologic/biochemical parameters and response to treatment. For the 27 dogs receiving single agent toceranib, an overall response rate of 10% was found. Overall median survival time was 823 days (range, 68-1190 days). The overall response rate for the dogs presenting with metastasis was 28.5%, with a median survival time of 532 days (range, 77-679 days). This was not significantly different than the median survival time of 796 days for dogs who did not present with metastasis. Of the dogs displaying clinical signs at the time of diagnosis, 90% had improvement and 81% had complete resolution of signs after starting toceranib. Toxicity was seen in 54% of dogs with gastrointestinal distress as the most common toxicity but dose reductions were infrequent required. Results demonstrate that toceranib phosphate is a well-tolerated and effective treatment for inoperable canine heart base tumours including dogs with advanced or metastatic disease.

Use of S-100 and Chromogranin A Antibodies as Immunohistochemical Markers on Detection of Malignancy in Aortic Body Tumors in Dog

To define the characteristics of malignancy we performed routine histology and an immunohistochemical study on seventeen aortic body tumors in dogs. We essayed tumors using a panel of immunohistochemical markers: neuron specific enolase (NSE), chromogranin A (CrA) and S-100. Among 17 cases, the neoplastic cells were positive for NSE (17 cases, 100%), S-100 (9 cases, 53%), and CrA (8 cases, 47%), respectively. The sustentacular cells density and chief cell staining intensity were both inversely related to tumor grade. The most relevant data was consistent with a negative staining of S-100 correlated with absence or decreased number of sustentacular cells in tumors grade III. This report indicates that the immunohistochemical panel has utility for the diagnosis of chemodectoma and the negative staining to CrA and S-100 markers in tumors grade III expresses an indication of malignant behaviour of the tumor.

Unusual metastasis of malignant aortic body tumor to multiple bones in a dog

Unusual metastasis of malignant aortic body tumor to multiple bones was detected in a 5-year-old female English Setter dog. Radiographs exhibited an abnormal mass in the base of heart and osteolytic lesions in the bodies of T11 and L2 vertebrates, body of right femur, right proximal humoral epiphysis and infraspinous fossa near to the neck of right scapula. At necropsy, multiple tumor masses of various sizes were observed also in the bones as well as the heart base and tracheobronchial lymph node. Tumor masses of L2 and T11 protruded into the vertebral canal and compressed corresponding sites of spinal cord, leading to paraplegia. Histopathologically, the tumor cells, arranged in sheets or nests, were polyhedral, lightly eosinophilic, finely granular cytoplasm with mostly round to oval nucleus and had scattered bizarre giant cells. Ultrastructural study revealed the characteristic findings that tumor cells contained a large number of small, electron-dense, membrane-limited secretory granules in cytoplasm. This is thought to be an extremely rare case having multiple bone metastases of a malignant aortic body tumor.

Analysis of factors affecting survival in dogs with aortic body tumors

OBJECTIVE

To evaluate the effect of perioperative and operative variables on survival time in dogs with aortic body tumors.

STUDY DESIGN

Retrospective study.

SAMPLE POPULATION

Twenty-four client-owned dogs with histologically confirmed aortic body tumor.

METHODS

Seventy-eight patient records of dogs seen at the University of Illinois Veterinary Teaching Hospital between 1989 and 1999 with a diagnosis of a heart-base mass were reviewed. Dogs without histologic conformation of an aortic body tumor were excluded. Age; sex; breed; the presence of pleural effusion, pericardial effusion, or abdominal effusion; evidence of cardiac arrhythmias; evidence of distant metastasis; treatment with pericardectomy; treatment with chemotherapy; and time from diagnosis until euthanasia or death were recorded on a spreadsheet. Cox proportional-hazard ratios were used to calculate the relationship of risk variables to survival time. Median survival time was determined using life-table analysis.

RESULTS

Twenty-four dogs met the criteria for inclusion in the study. The median age of dogs with aortic body tumors was 9 years. All dogs had a surgical biopsy performed. Fourteen dogs had a pericardectomy at the time of the biopsy procedure. Of all factors analyzed, only treatment with pericardectomy had a significant influence on survival (P =.0029). Dogs that had pericardectomy survived longer (median survival, 730 days; range, 1-1,621 days) compared with dogs that did not have pericardectomy (median survival, 42 days; range, 1-180 days). This finding was independent of the presence or absence of pericardial effusion at the time of surgery.

CLINICAL RELEVANCE

Dogs that are diagnosed with aortic body tumors may benefit from a pericardectomy at the time of surgical biopsy.

Posterior mediastinal paraganglioma involving the spinal cord of a dog

A posterior mediastinal paraganglioma is described in a five-year-old female collie showing paralysis of the hindlimbs. The mass was observed radiographically and a myelogram confirmed a spinal cord compression at the thoracic level. Histological examination of the mass diagnoses a paraganglioma which was confirmed by histochemical and immunohistochemical studies. This is compared with paraganglioma found in man.

Neoplastic diseases of the thorax

Thoracic neoplasia comprises a heterogeneous group of diseases, many of which are distinctly uncommon in veterinary medicine. These diseases often present the clinician with diagnostic and therapeutic challenges. Careful diagnostic work-up and staging are essential for consideration of therapeutic options and formulation of prognosis. Neoplastic diseases of the thorax are classified here as tracheal tumors, primary lung tumors, nonrespiratory intrathoracic tumors, and thoracic wall tumors.

Aortic body tumour with adjacent ectopic thyroid tissue in a dog

A 12-year-old neutered male Husky dog had a neoplasm at the base of the heart which did not invade surrounding tissues. Microscopically, the neoplasm was composed of nests and sheets of polyhedral cells subdivided into lobules by trabeculae of fine fibrovascular stroma. Adjacent to the neoplasm was a rim of ectopic thyroid tissue that appeared histologically normal. The possible differential diagnoses for the neoplasm were aortic body tumour, ectopic thyroid tumour and ectopic parathyroid tumour; the ultrastructural characteristics revealed it to be an aortic body tumour.

Ectopic thyroid carcinoma with metastases in a beagle dog

A 10.25-year-old female beagle had an invasive neoplasm at the base of the heart which metastasized to the lungs, pancreas, and kidney. The neoplasm in these locations was composed of clusters of polyhedral cells surrounded by fine fibrovascular stroma. The differential diagnoses were malignant chemodectoma, ectopic parathyroid carcinoma, and ectopic thyroid carcinoma. Based on ultrastructural features, this tumor was an ectopic thyroid carcinoma.